Androgen Deprivation Therapy Market Growth & Trends [2031]

Report Description

Androgen Deprivation Therapy Market Outlook 2031

The global androgen deprivation therapy market size was USD XX Million in 2022 and is likely to reach USD XX Million by 2031, expanding at a CAGR of XX% during 2023–2031. The market growth is attributed to the increasing awareness of prostate cancer among individuals and rising research & development activities to improve the safety profile of androgen deprivation therapy.

Rising integration of advanced Artificial Intelligence (AI) technologies in treatment planning and the development of personalized medicine is anticipated to boost the market. Growing emphasis on early detection of cancer and the adoption of comprehensive treatment approaches contribute to the increased use of androgen deprivation therapy.

Get Free Sample Report

Increasing geriatric population across the globe boosts the demand for androgen deprivation therapy (ADT), as older people are often susceptible to hormone-dependent conditions, including prostate cancer. However, prostate cancer often depends on male hormones called testosterone to grow. Androgen deprivation therapy aims to reduce the production or action of this hormone to slow down the development of prostate cancer cells. Moreover, innovative technologies such as advanced diagnostics, personalized treatment plans, and telehealth integration enhance the overall therapy experience.

The market report finds that the COVID-19 pandemic hampered the androgen deprivation therapy market. The COVID-19 pandemic led to disruptions in healthcare services across the globe. Many non-essential medical procedures, including routine cancer screenings and treatments, were delayed or postponed to prioritize resources for COVID-19 patients. For instance,

• According to the data published by the National Institute of Health in July 2022, the COVID-19 pandemic led to a sharp decline in cancer screening rates worldwide, affecting all types of cancer, age groups, and racial/ethnic communities. Around 19.3 million new cases and approximately 10 million cancer-related deaths were reported across the globe in 2020.

Impact of Artificial Intelligence (AI) on the Androgen Deprivation Therapy Market

Artificial Intelligence (AI) is expected to boost the revenue of the market players present in the androgen deprivation therapy market. AI has the potential to analyze vast amounts of patient data, including genetic information, pathology reports, and imaging results. This enables healthcare providers to develop personalized and targeted treatment plans for individuals undergoing ADT by considering specific characteristics of their cancer. For instance,

• According to a recent research study conducted in June 2023, ArteraAI, a developer specializing in multimodal AI-based predictive and prognostic cancer tests, collaborated with researchers, including those from University Hospitals (UH) Seidman Cancer Center, and developed the first AI-based predictive biomarkers. These biomarkers aid in assessing the benefits of ADT in prostate cancer that are personalized.

Androgen Deprivation Therapy Market Dynamics

Get Free Sample Report

Major Drivers

Rising prevalence of prostate cancer drives the market. Prostate cancer prevalence rates are high, particularly among the elderly population. The risk of developing prostate cancer increases with age. Thus, the growing geriatric population across the globe contributes to the growth of the market. Furthermore, the increasing incidence of prostate cancer globally boosts the demand for effective treatments, including ADT. For instance,

• As per a report published in 2023 by the Cancer.Net Editorial Board, approximately 288,300 men in the US are projected to receive a prostate cancer diagnosis in 2023. An estimated 1,414,259 individuals were diagnosed with prostate cancer globally in 2020.

Existing Restraints

High cost associated with androgen deprivation therapy hampers the market. ADT often involves the use of medications, such as luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. These drugs are expensive, thereby affecting the market. Moreover, the need for long-term or ongoing treatment contributes to the overall financial burden on patients, which restrains the market.

Emerging Opportunities

Rising technological advancements in drug delivery systems create lucrative opportunities in the market. Technological advancements in drug delivery systems allow for precise and targeted delivery of androgen deprivation therapy medications. This leads to improved treatment efficacy by ensuring that the therapeutic agents reach their intended targets with accuracy. This further minimizes side effects and enhances the overall effectiveness of the therapy.

Scope of the Androgen Deprivation Therapy Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the androgen deprivation therapy market is divided into LHRH agonists, LHRH antagonists, antiandrogens, and others. The antiandrogens segment is expected to hold the major share of the market during the projection period, as it improves prostate cancer treatment and management of hormone-dependent conditions.

Antiandrogens play a crucial role in the treatment of prostate cancer by inhibiting the activity of male hormones (androgens), which are known to promote the growth of prostate cancer cells.

It is used in the management of various hormone-dependent conditions, including hirsutism, acne, and certain types of hair loss. This broadens the scope of their usage, thereby boosting the segment. For instance,

• In March 2023, Nubeqa (darolutamide) received approval from the European Commission for an oral androgen receptor inhibitor (ARi), in combination with androgen deprivation therapy (ADT) and docetaxel for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The luteinizing hormone-releasing hormone (LHRH) agonists segment is expected to expand at a significant growth rate, as it provides a mechanism of action for ADT. LHRH agonists function by inhibiting the production of luteinizing hormone (LH) in the body, which leads to a reduction in the production of testosterone. Testosterone is a key androgen that helps to grow prostate cancer cells. The mechanism of action of LHRH agonists aligns with the goal of ADT making them an essential therapeutic approach.

Mode of Administration Segment Analysis

On the basis of mode of administration, the global market is bifurcated into oral and injectable. The injectable segment is projected to register a high CAGR during the forecast period, as it offers effective drug delivery and minimizes the risk of medication errors.

Injectable formulations provide an efficient and direct avenue of drug delivery, ensuring that the therapeutic agents are rapidly released into the bloodstream. This allows for a quick onset of action, a critical factor in the management of conditions, such as prostate cancer, where timely hormone suppression is essential. Injectable formulation minimizes the risk of medication errors and enhances the overall safety and efficacy of the therapy.

Distribution Channel Segment Analysis

Based on distribution channel, the androgen deprivation therapy market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The hospital pharmacies segment is anticipated to register a robust growth rate during the forecast period, due to the increasing incidence of prostate cancer and the growing aging population.

The demand for ADT is rising, due to a high incidence rate of prostate cancer, prompting an increased need for pharmaceuticals associated with androgen deprivation therapy. The risk of prostate cancer is high in older individuals. Thus, the demand for ADT is expected to increase, with the growing geriatric population across the globe. This results in increased sales and distribution of prostate cancer-related drugs through hospital pharmacies.

The retail pharmacies segment is anticipated to expand at a significant pace, as it offers convenience to patients. Retail pharmacies are easily accessible to a wide range of patients, offering convenience in terms of location and opening hours. This accessibility encourages individuals undergoing androgen deprivation therapy to obtain their prescribed medications conveniently. Retail pharmacies typically have an extensive network of outlets, covering urban and rural areas uniformly. This widespread presence ensures that a large population has access to ADT medications.

Regional Outlook

In terms of region, the global androgen deprivation therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the rising incidence of prostate cancer and advanced healthcare infrastructure in the region.

North America, including the US and Canada, has a relatively high prevalence rate of prostate cancer. Prostate cancer requires androgen deprivation therapy, which contributes to a significant demand for this treatment. Additionally, the region is recognized for its advanced and well-established healthcare infrastructure, which provides access to state-of-the-art diagnostic tools, treatment options, and medical expertise. For instance,

• According to data published by the American Cancer Society in 2023, approximately 1,958,310 new cancer cases and an estimated 609,820 cancer-related deaths in the US are expected to be reported in 2023.

The market in Europe is projected to grow rapidly during the forecast period, owing to the growing government initiatives and rising research & innovation in advanced ADT solutions. Europe has robust healthcare policies that focus on cancer prevention, early detection, and advanced treatment strategies, enhancing patient access to androgen deprivation therapy. Furthermore, ongoing research activities and collaborations between pharmaceutical companies, research institutions, and healthcare providers contribute to the development and adoption of advanced ADT solutions.

Get Free Sample Report